J&J Immunotherapy Darzalex Ok’d for Expanded Combination Use – Zacks.com
|
J&J Immunotherapy Darzalex Ok'd for Expanded Combination Use
Zacks.com Johnson & Johnson (JNJ – Free Report) announced that its immunotherapy, Darzalex has been approved for use in combination with Celgene Corporation's (CELG – Free Report) multiple myeloma drug Pomalyst (pomalidomide) and dexamethasone. |
